Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans

By Hiroshi Watanabe, Nagesh Chopra, D. Laver, H. Hwang, S. Davies, D. Roach, H. Duff, D. Roden, A. Wilde, B. Knollmann. Nature Medicine, 2009

602 citations recorded by the source corpus.

Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a potentially lethal inherited arrhythmia syndrome in which drug therapy is often ineffective. We discovered that flecainide prevents arrhythmias in a mouse model of CPVT by inhibiting cardiac ryanodine receptor–mediated Ca2+ release and thereby directly targeting the underlying molecular defect. Flecainide completely prevented CPVT in two human subjects who had remained highly symptomatic on conventional drug therapy, indicating that this currently available drug is a promising mechanism-based therapy for CPVT.

Subfields: Cardiology and Cardiovascular Medicine, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/a1806d9b25d4ae28cf758d4660057893e567cf38

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. Xiaobo Mao
2. Gui-wen Yi

Citations in the corpus

• 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the preventionof sudden cardiac death (2015, positive): “Preliminary data suggest that flecainide significantly reduces the VA burden in a limited number of patients with CPVT and should be considered as the first addition to beta-blockers when control of arrhythmias is incomplete.(462,463) Left cardiac sympathetic denervation seems to have some degree of”